The recent trade deadline in Major League Baseball was marked by a series of dramatic moves, and one of the most notable involved right-hander Jack Flaherty, who was traded to the Los Angeles Dodgers. The process, however, was far from straightforward and came with its share of twists and turns.
Yankees' Hesitation Over Medical Records
Initially, it seemed that the New York Yankees were poised to acquire Flaherty. The Yankees had reached a preliminary agreement with the Detroit Tigers, ready to bolster their pitching staff with the right-hander's talents. However, after a detailed review of Flaherty's medical records, the Yankees decided to rescind their agreement. Flaherty's history of shoulder troubles in 2021 and 2022, alongside a more recent lower back issue that required two injections in early July, raised too many red flags for the Bronx Bombers.
The Yankees' caution is understandable, given their previous experiences. Two years ago, they acquired Frankie Montas, who also had a history of shoulder inflammation. Montas underwent surgery the following spring and missed nearly the entire season, an ordeal the Yankees were likely wary of repeating with Flaherty.
The Dodgers Step In
With the Yankees stepping back, the Los Angeles Dodgers seized the opportunity. The Dodgers were undeterred by Flaherty's medical history and moved swiftly to acquire him from the Tigers. In exchange, they sent two prospects—catcher/first baseman Thayron Liranzo and shortstop Trey Sweeney—to Detroit.
This move was part of a broader strategy by the Dodgers to fortify their pitching rotation in preparation for a deep postseason run. Flaherty's impressive performance this season was undoubtedly a factor in their decision. He made 18 starts for the Tigers, posting a 2.95 ERA with 33 strikeouts in 106 2/3 innings. More recently, he had showcased his prowess with a 2.08 ERA and a .560 opponent's OPS in his last seven innings.
Calculated Risk for the Dodgers
For the Dodgers, acquiring Flaherty is a calculated risk. His recent lower back issue, which caused him to miss a start and required injections, does add an element of uncertainty. However, the Dodgers are banking on his ability to stay healthy and contribute meaningfully to their rotation. Dodgers manager Dave Roberts confirmed that Flaherty will make his first start for the team this weekend against the Oakland Athletics, marking a new chapter in his career.
Scott Harris, the president of the Tigers, addressed the situation but kept the focus away from the medical aspects. "I can't comment on medical stuff with trades as a general point. And if medical stuff did affect any of the trades, that's not on our end. You can't ask me about that because we're not the one trading for Jack, so not commenting on any of that stuff because I can't," Harris said.
Looking Ahead
As the Dodgers prepare to integrate Flaherty into their rotation, their confidence in his abilities is clear. The decision to move forward with the trade despite potential medical concerns reflects their commitment to strengthening their roster and their belief in Flaherty's potential to make a significant impact.
The baseball world will be watching closely as Flaherty takes the mound for his new team. His performance in the coming weeks will not only influence the Dodgers' postseason prospects but could also shape the perception of this high-profile trade as the season progresses.